A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 mg to 18 mg Once Daily and LY2216684 Fixed-Dose 6 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment.

Trial Profile

A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 mg to 18 mg Once Daily and LY2216684 Fixed-Dose 6 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Edivoxetine (Primary)
  • Indications Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 27 Sep 2016 Results of pooled analysis from 4 adjunctive treatment trials and 1 monotherapy trial (n=2561) published in the Journal of Clinical Psychiatry.
    • 01 Mar 2016 Results of pooled analysis of this and other 2 trials (NCT01173601 and NCT01185340) published in the Journal of Clinical Psychiatry
    • 05 Dec 2013 Results will be reported during 2014, according to an Eli Lilly media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top